These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34254992)

  • 1. Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?
    Crosson FJ; Covinsky K; Redberg RF
    JAMA Intern Med; 2021 Oct; 181(10):1278-1280. PubMed ID: 34254992
    [No Abstract]   [Full Text] [Related]  

  • 2. Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective.
    Dunn B; Stein P; Cavazzoni P
    JAMA Intern Med; 2021 Oct; 181(10):1276-1278. PubMed ID: 34254984
    [No Abstract]   [Full Text] [Related]  

  • 3. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 4. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 5. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    Schulman KA; Greicius MD; Richman B
    JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicare Coverage of Aducanumab - Implications for State Budgets.
    Sachs RE; Bagley N
    N Engl J Med; 2021 Nov; 385(22):2019-2021. PubMed ID: 34797617
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.
    Moghavem N; Henderson VW; Greicius MD
    Ann Neurol; 2021 Sep; 90(3):331-333. PubMed ID: 34278596
    [No Abstract]   [Full Text] [Related]  

  • 8. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
    Planche V; Villain N
    JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
    [No Abstract]   [Full Text] [Related]  

  • 9. Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.
    Robinson JC
    N Engl J Med; 2021 Nov; 385(22):2017-2019. PubMed ID: 34797614
    [No Abstract]   [Full Text] [Related]  

  • 10. Aducanumab and Accelerated Approval: Where Do We Go From Here?
    Kesselheim AS
    Clin Pharmacol Ther; 2022 Apr; 111(4):726-727. PubMed ID: 35174494
    [No Abstract]   [Full Text] [Related]  

  • 11. What to Know About the Alzheimer Drug Aducanumab (Aduhelm).
    Woloshin S; Kesselheim AS
    JAMA Intern Med; 2022 Aug; 182(8):892. PubMed ID: 35666531
    [No Abstract]   [Full Text] [Related]  

  • 12. [Not Available].
    Watt JA; Marple R; Hemmelgarn B; Straus SE
    CMAJ; 2021 Nov; 193(43):E1680-E1682. PubMed ID: 34725122
    [No Abstract]   [Full Text] [Related]  

  • 13. [Aducanumab and Alzheimer's disease: a critical reflection.].
    Vanacore N; Blasimme A; Canevelli M
    Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    Alexander GC; Emerson S; Kesselheim AS
    JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
    [No Abstract]   [Full Text] [Related]  

  • 15. Aducanumab Fails to Produce Efficacy Results Yet Obtains US Food and Drug Administration Approval.
    Angelo M; Ward L
    Popul Health Manag; 2021 Dec; 24(6):638-639. PubMed ID: 34516238
    [No Abstract]   [Full Text] [Related]  

  • 16. Alzheimer's and Aducanumab: Unjust Profits and False Hopes.
    Fleck LM
    Hastings Cent Rep; 2021 Jul; 51(4):9-11. PubMed ID: 34156732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversial Approval of New Drug to Treat Alzheimer's Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
    Anderson TS; Ayanian JZ; Souza J; Landon BE
    JAMA; 2021 Oct; 326(16):1627-1629. PubMed ID: 34499725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A carte blanche approval in Alzheimer's.
    Nat Biotechnol; 2021 Jul; 39(7):781. PubMed ID: 34183862
    [No Abstract]   [Full Text] [Related]  

  • 20. Off-label use of aducanumab for cerebral amyloid angiopathy.
    Greenberg SM; Cordonnier C; Schneider JA; Smith EE; van Buchem MA; van Veluw SJ; Verbeek MM; Viswanathan A; Werring DJ
    Lancet Neurol; 2021 Aug; 20(8):596-597. PubMed ID: 34237272
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.